Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease remains without a disease‐modifying therapy that improves symptoms after therapy withdrawal. Because no investigational agents have demonstrated disease‐modifying effects clinically, we tested whether the Fyn inhibitor, saracatinib, provides persistent improvement in a transgenic model. Aged APPswe/PS1&Dgr;E9 mice were treated with saracatinib or memantine for 4 weeks and spatial memory improved to control levels. After drug washout, there was sustained rescue of both memory function and synapse density by saracatinib, but a loss of benefit from memantine. These data demonstrate a disease‐modifying persistent benefit for saracatinib in a preclinincal Alzheimer's model, and distinguish its action from that of memantine. HIGHLIGHTSDisease‐modifying effects of saracatinib or memantine were assessed in vivo.Saracatinib but not memantine exhibited persistent rescue of synapses and memory.Saracatinib benefit was observed at least one month after therapy discontinuation.Withdrawal study design can differentiate disease‐modifying and symptomatic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 2×
“Fyn has been studied as a Tau kinase, and is a key connection of Amyloid beta oligomers (Abo) to tauopathy (Chin et al., 2004, 2005; Ittner et al., 2010; Kaufman et al., 2015; Larson et al., 2012; Lee et al., 1998; Roberson et al., 2011; Rushworth et al., 2013; Shirazi and Wood, 1993; Um et al., 2012).”
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 4×
“By 2050, Alzheimer's disease is projected to account for 43% of adult deaths in the United States (Weuve et al., 2014).”
InfluentialJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“Wild type and APPswe/PS1DE9 mice (Jankowsky et al., 2004) were purchased from Jackson Laboratory and maintained on a C57/Bl6J background as described previously (Gimbel et al., 2010; Um et al., 2012, 2013).”
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Self-citationTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
The dentate gyrus: fundamental neuroanatomical organization (dentate gyrus for dummies)
Amaral, D. G., Scharfman, H. E., & Lavenex, P. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)63001-5 · Cited by 888 · cited 1×
“For PSD95, three slices per animal were imaged and for each slice, three images in the polymorphic layer of the dentate gyrus were collected (Amaral et al., 2007).”
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · cited 2×
“This stands in stark contrast to the pathology observed in human patients in which clinical symptoms are not apparent until amyloidosis has plateaued, neuroinflammation is ongoing, and neurodegeneration is well established (Morris and Price, 2001; Perrin et al., 2009; Shi et al., 2009; Tarkowski et al., 2003; Xiang et…”
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654 · cited 1×
“…has been studied as a Tau kinase, and is a key connection of Amyloid beta oligomers (Abo) to tauopathy (Chin et al., 2004, 2005; Ittner et al., 2010; Kaufman et al., 2015; Larson et al., 2012; Lee et al., 1998; Roberson et al., 2011; Rushworth et al., 2013; Shirazi and Wood, 1993; Um et al., 2012).”
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Self-citationAlzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513 · cited 2×
“This stands in stark contrast to the pathology observed in human patients in which clinical symptoms are not apparent until amyloidosis has plateaued, neuroinflammation is ongoing, and neurodegeneration is well established (Morris and Price, 2001; Perrin et al., 2009; Shi et al., 2009; Tarkowski et al., 2003; Xiang et…”
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502 · cited 2×
“It is important to note that while the APP23 mouse model exhibits impairments in the Morris water maze at three months of age, this is prior to the development of plaques, gliosis, and synapse loss (Boncristiano et al., 2005; Calhoun et al., 1998; Kelly et al., 2003; Reichwald et al., 2009; Sturchler-Pierrat et al., 1…”
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 2×
“This stands in stark contrast to the pathology observed in human patients in which clinical symptoms are not apparent until amyloidosis has plateaued, neuroinflammation is ongoing, and neurodegeneration is well established (Morris and Price, 2001; Perrin et al., 2009; Shi et al., 2009; Tarkowski et al., 2003; Xiang et…”
Shi, F., Liu, B., Zhou, Y., Yu, C., & Jiang, T. (2009) · Hippocampus · doi:10.1002/hipo.20573 · Cited by 470 · cited 3×
“This stands in stark contrast to the pathology observed in human patients in which clinical symptoms are not apparent until amyloidosis has plateaued, neuroinflammation is ongoing, and neurodegeneration is well established (Morris and Price, 2001; Perrin et al., 2009; Shi et al., 2009; Tarkowski et al., 2003; Xiang et…”
Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein
Gimbel, D. A., Nygaard, H. B., Coffey, E. E., Gunther, E. C., Laurén, J., Gimbel, Z. A., & Strittmatter, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0395-10.2010 · Cited by 418
Self-citationFyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · cited 12×
“Morris water maze testing was conducted as described (Haas et al., 2017; Kaufman et al., 2015; Morris, 1984; Um et al., 2013).”
InfluentialSelf-citationDeaths in the United States among persons with Alzheimer's disease (2010–2050)
Weuve, J., Hebert, L. E., Scherr, P. A., & Evans, D. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.004 · Cited by 173
Masitinib for the treatment of mild to moderate Alzheimer’s disease
Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80 · cited 1×
“Although another kinase inhibitor, masitinib, is less potent and less selective than saracatinib as a Fyn inhibitor, the potential utility of both compounds in AD may depend on Fyn inhibition (Folch et al., 2015; Nygaard, 2017; Piette et al., 2011).”
Boncristiano, S., Calhoun, M. E., Howard, V., Bondolfi, L., Kaeser, S. A., Wiederhold, K.-H., Staufenbiel, M., & Jucker, M. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.010 · Cited by 68 · cited 2×
“It is important to note that while the APP23 mouse model exhibits impairments in the Morris water maze at three months of age, this is prior to the development of plaques, gliosis, and synapse loss (Boncristiano et al., 2005; Calhoun et al., 1998; Kelly et al., 2003; Reichwald et al., 2009; Sturchler-Pierrat et al., 1…”
Cited by
Gomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
Socodato, R., Portugal, C. C., Canedo, T., Rodrigues, A., Almeida, T. O., Henriques, J. F., Vaz, S. H., Magalhães, J., Silva, C. M., Baptista, F. I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107796 · Cited by 94
“002 mg/kg) we tested produced around 30% of Src inhibition, these data show that the dosage of AZD 0530 we used effectively sustained Src inhibition in the brain, which is in accordance with a persistent effect of AZD 0530 reported for APP/PS1 mice after drug washout (Smith et al., 2018).”
MethodToyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79
“Treatment Following protocols previously used (9,10), saracatinib (5 mg/kg orally every 12 h) was administered to WT and APP/PS1 mice for 40.”
BackgroundMethodResultInfluentialSelf-citationPTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease
Giralt, A., de Pins, B., Cifuentes-Díaz, C., López-Molina, L., Farah, A. T., Tible, M., Deramecourt, V., Arold, S. T., Ginés, S., Hugon, J., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.05.020 · Cited by 64
Visser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
“Preclinical studies suggest potential medications for AD may enhance synaptic density (Kaufman et al., 2015; Smith et al., 2018; Toyonaga et al., 2019).”
Background
Metadata
- Authors
- Smith, L. M., Zhu, R., & Strittmatter, S. M.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 130
- Pages
- 54-61
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2768778622
- Cited by
- 47
- References
- 19
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.